Wainberg ZA, et al., A double-blind randomized study of bemarituzumab (bema) plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line treatment for advanced gastric/gastroesophageal junction cancer (FIGHT), Journal of Clinical Oncology 2021; 39:3_suppl: 160-160.
Wainberg ZA, et al., A double-blind randomized study of bemarituzumab (bema) plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line treatment for advanced gastric/gastroesophageal junction cancer (FIGHT), Journal of Clinical Oncology 2021; 39:3_suppl: 160-160.